Gossamer Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 179.82 million compared to USD 229.38 million a year ago. Basic loss per share from continuing operations was USD 1.18 compared to USD 2.71 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.668 USD | -0.30% | -14.77% | -26.79% |
Mar. 13 | Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM | |
Mar. 12 | Gossamer Bio Announces Board of Directors Appointments | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.79% | 151M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- GOSS Stock
- News Gossamer Bio, Inc.
- Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023